Pharmacoinformatic approaches to design natural product type ligands of ABC-transporters

Current Pharmaceutical Design

Volumn 16, Issue 15, 2010, Pages 1742-1752

  Klepsch, F ^a   Jabeen, I ^a   Chiba, P ^b   Ecker, G F ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

ABC transporter; In silico methods; Natural products; P glycoprotein

Indexed keywords

ABC TRANSPORTER; ALDOSTERONE; ANDROSTANOLONE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CHALCONE DERIVATIVE; CORTICOSTERONE; CORTODOXONE; CYCLOSPORIN DERIVATIVE; DEXAMETHASONE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; HYDROCORTISONE; HYDROXYPROGESTERONE; ISOFLAVONE; MEDROXYPROGESTERONE ACETATE; MULTIDRUG RESISTANCE PROTEIN 1; PHENOTHIAZINE DERIVATIVE; PRASTERONE; PREGNENOLONE; PROGESTERONE; PROPAFENONE; PROTEIN INHIBITOR; TESTOSTERONE; THIOXANTHENE DERIVATIVE; TRIAZINE DERIVATIVE; UNINDEXED DRUG; VERAPAMIL DERIVATIVE; BIOLOGICAL PRODUCT; FLAVONOID; GLYCOPROTEIN P; LIGAND; MULTIDRUG RESISTANCE PROTEIN; SESQUITERPENE; STEROID; TUMOR PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; COMPUTER ANALYSIS; COMPUTER MODEL; DRUG ACTIVITY; DRUG BINDING SITE; DRUG DESIGN; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; REVIEW;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; LIGANDS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; SESQUITERPENES; STEROIDS;

EID: 77957975632     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161210791163992     Document Type: Article

References (71)

1. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 2006; 580: 998-1009.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
3. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967-1972.
4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
5. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-1017.
6. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13: 379-393.
7. Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 2006; 3: 3-25.
8. Pleban K, Ecker GF. Inhibitors of p-glycoprotein--lead identification and optimisation. Mini Rev Med Chem 2005; 5: 153-163.
9. Zhang S, Yang X, Coburn RA, Morris ME. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol 2005; 70: 627-639.
10. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004; 65: 1208-1216.
11. Bansal T, Jaggi M, Khar RK, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci 2009; 12: 46-78.
12. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, Di Pietro A. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 1998; 95: 9831-9836.
13. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF. Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2. ChemMedChem 2007; 2: 1783-1788.
14. Free SM, Jr., Wilson JW. A Mathematical contribution to structure-activity studies. J Med Chem 1964; 7: 395-399.
15. Pick A, Muller H, Wiese M. Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2008; 16: 8224-8236.
16. Ueda K, Saeki T, Hirai M, Tanigawara Y, Tanaka K, Okamura M, et al. Human P-glycoprotein as a multi-drug transporter analyzed by using transepithelial transport system. Jpn J Physiol 1994; 44 (Suppl 2): S67-S71.
17. Yang CP, DePinho SG, Greenberger LM, Arceci RJ, Horwitz SB. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989; 264: 782-788.
18. Hamilton KO, Yazdanian MA, Audus KL. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int J Pharm 2001; 228: 171-179.
19. Li Y, Wang YH, Yang L, Zhang SW, Liu CH, Yang SL. Comparison of steroid substrates and inhibitors of P-glycoprotein by 3D-QSAR analysis. J Mol Structure 2005; 733: 111-118.
20. Barnes KM, Dickstein B, Cutler GB, Jr., Fojo T, Bates SE. Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996; 35: 4820-4827.
21. Muñoz-Martínez F, Reyes CP, Pérez-Lomas AL, Jiménez IA, Gamarro F, Castanys S. Insights into the molecular mechanism of action of Celastraceae sesquiterpenes as specific, non-transported inhibitors of human P-glycoprotein. Biochimica et Biophysica Acta (BBA) - Biomembranes 2006; 1758: 98-110.
22. Reyes CP, Munoz-Martinez F, Torrecillas IR, Mendoza CR, Gamarro F, Bazzocchi IL, et al. Biological evaluation, structure-activity relationships, and three-dimensional quantitative structure-activity relationship studies of dihydro-beta-agarofuran sesquiter-penes as modulators of P-glycoprotein-dependent multidrug resistance. J Med Chem 2007; 50: 4808-4817.
23. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat Rev Mol Cell Biol 2009; 10: 218-227.
24. Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int J Cancer 2002; 97: 626-630.
25. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337-5339.
26. Seeger MA, van Veen HW. Molecular basis of multidrug transport by ABC transporters. Biochim Biophys Acta 2009; 1794: 725-737.
27. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 2006; 443: 180-185.
28. Becker JP, Depret G, Van Bambeke F, Tulkens PM, Prevost M. Molecular models of human P-glycoprotein in two different catalytic states. BMC Struct Biol 2009; 9: 3.
29. Globisch C, Pajeva IK, Wiese M. Identification of putative binding sites of P-glycoprotein based on its homology model. Chem Med Chem 2008; 3: 280-295.
30. Stockner T, de Vries SJ, Bonvin AM, Ecker GF, Chiba P. Data-driven homology modelling of P-glycoprotein in the ATP-bound state indicates flexibility of the transmembrane domains. FEBS J 2009; 276: 964-972.
31. DeGorter MK, Conseil G, Deeley RG, Campbell RL, Cole SP. Molecular modeling of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochem Biophys Res Commun 2008; 365: 29-34.
32. Hazai E, Bikadi Z. Homology modeling of breast cancer resistance protein (ABCG2). J Struct Biol 2008; 162: 63-74.
33. O'Mara ML, Tieleman DP. P-glycoprotein models of the apo and ATP-bound states based on homology with Sav1866 and MalK. FEBS Lett 2007; 581: 4217-4222.
34. Dawson RJ, Locher KP. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Lett 2007; 581: 935-938.
35. Ward A, Reyes CL, Yu J, Roth CB, Chang G. Flexibility in the ABC transporter MsbA: Alternating access with a twist. Proc Natl Acad Sci USA 2007; 104: 19005-19010.
36. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323: 1718-1722.
37. Pajeva IK, Globisch C, Wiese M. Combined pharmacophore modeling, Docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors. Chem Med Chem 2009; 4(11): 1883-1896.
38. Loo TW, Clarke DM. The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J Biol Chem 1999; 274: 24759-24765.
39. Loo TW, Clarke DM. Mutational analysis of ABC proteins. Arch Biochem Biophys 2008; 476: 51-64.
40. Shilling RA, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S, et al. New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci 2006; 27: 195-203.
41. Loo TW, Clarke DM. Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 2002; 277: 44332-44338.
42. Qu Q, Sharom FJ. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet. Biochemistry 2002; 41: 4744-4752.
43. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 2000; 58: 624-632.
44. Shapiro AB, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site. Eur J Biochem 1999; 259: 841-850.
45. Loo TW, Bartlett MC, Clarke DM. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. Biochem J 2006; 399: 351-359.
46. Loo TW, Clarke DM. Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. J Biol Chem 1997; 272: 31945-31948.
47. Clark R, Kerr ID, Callaghan R. Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 2006; 149: 506-515.
48. Deeley RG, Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 2006; 580: 1103-1111.
49. Matsson P, Pedersen JM, Norinder U, Bergstrom CA, Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009; 26: 1816-1831.
50. Ramaen O, Leulliot N, Sizun C, Ulryck N, Pamlard O, Lallemand JY, et al. Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a nonproductive catalytic site. J Mol Biol 2006; 359: 940-949.
51. Mares-Samano S, Badhan R, Penny J. Identification of putative steroid-binding sites in human ABCB1 and ABCG2. Eur J Med Chem 2009; 44: 3601-3611.
52. Badhan R, Penny J. In silico modelling of the interaction of flavonoids with human P-glycoprotein nucleotide-binding domain. Eur J Med Chem 2006; 41: 285-295.
53. Aszalos A. Role of ATP-binding cassette (ABC) transporters in interactions between natural products and drugs. Curr Drug Metab 2008; 9: 1010-1018.
54. Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res 2009; 26: 883-892.
55. Dasgupta A, Reyes MA, Risin SA, Actor JK. Interaction of white and pink grapefruit juice with acetaminophen (paracetamol) in vivo in mice. J Med Food 2008; 11: 795-798.
56. Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, et al. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 2008; 87: 863-871.
57. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005; 22: 11-23.
58. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev 2008; 60: 717-733.
59. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, et al. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 1992; 51: 1427-1437.
60. Borst P, Schinkel AH. Introduction to the blood-brain barrier. In: Partridge WM, Ed. Cambridge: Cambridge University Press 1998; pp. 198-206.
61. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004; 21: 25-51.
62. Chiba P, Ecker GF, Eds. Transporters as Drug Carriers. Weinheim: Wiley-VCH 2009; pp. 349-359.
63. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129-137.
64. Labute P. A widely applicable set of descriptors. J Mol Graph Model 2000; 18: 464-477.
65. Kaiser D, Terfloth L, Kopp S, Schulz J, de Laet R, Chiba P, et al. Self-organizing maps for identification of new inhibitors of P-glycoprotein. J Med Chem 2007; 50: 1698-1702.
66. Zdrazil B, Prakasvudhisarn C, Ecker GF. NCI60 screening data - a versatile tool for in silico models predicting substrate properties for ABC-transporter. ACS 234th National Meeting & Exposition. Boston 2007.
67. Sakurai A, Onishi Y, Hirano H, Seigneuret M, Obanayama K, Kim G, et al. Quantitative structure--activity relationship analysis and molecular dynamics simulation to functionally validate nonsy-nonymous polymorphisms of human ABC transporter ABCB1 (P-glycoprotein/MDR1). Biochemistry 2007; 46: 7678-7693.
68. Rosenberg MF, Kamis AB, Callaghan R, Higgins CF, Ford RC. Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major conformational changes in the transmembrane domains upon nucleotide binding. J Biol Chem 2003; 278: 8294-8299.
69. Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC. Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem 2005; 280: 2857-2862.
70. Rosenberg MF, Mao Q, Holzenburg A, Ford RC, Deeley RG, Cole SP. The structure of the multidrug resistance protein 1 (MRP1/ABCC1). crystallization and single-particle analysis. J Biol Chem 2001; 276: 16076-16082.
71. McDevitt CA, Collins RF, Conway M, Modok S, Storm J, Kerr ID, et al. Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure 2006; 14: 1623-1632.